A Phase 2 interventional study of Gabapentin Extended Release tablets and Gabapentin in Hot Flashes, sponsored by Depomed. Completed at 8 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-08.
Sponsored by Depomed · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing gabapentin in Hot Flashes — none open to participants now, none under way, none of them phase 3. Gabapentin · Hot Flashes.
Among the 11 studies testing gabapentin in Hot Flashes, this one is the 8th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 2, and was the 5th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →None of the 11 studies testing gabapentin in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →
Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 160 across the 10 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 7 most frequent:
Depomed is the lead sponsor of 14 studies on the registry; none are open to participants now.
Depomed has 4 studies filed under Hot Flashes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing gabapentin in Hot Flashes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Depomed's Gabapentin Extended Release is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women.
The primary objective of this clinical trial is to determine the optimal dose of Gabapentin ER in reducing the number and severity of hot flashes in postmenopausal women. Patients will be randomly assigned to Gabapentin ER or placebo, with a 1 in 4 chance of getting placebo. The total study investigational treatment duration after screening and baseline will be 13 weeks. The primary endpoint of the trial is to compare the number and severity of hot flashes during the investigational treatment compared to baseline. Sleep quality will also be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Other inclusions apply.
Exclusion Criteria:
Other exclusions apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active drug, Gabapentin extended release
Drug: Gabapentin Extended Release tablets · Drug: Gabapentin
Comparator arm is Placebo
Drug: Gabapentin Extended Release tablets · Drug: Gabapentin
1800mg
1800mg
Frequency of moderate to severe hot flashes reported during the corresponding 24- hour blood samples collection period
PD end points are considered as primary outcomes of this study
Time frame: 24hrs
CGIC and PGIC evaluated prior to the start of 24- hour blood samples at week 6 and week 12 visits.
Efficacy variables
Time frame: 12 wks
The record gives a start of Jun 2007, a primary completion of Dec 2007 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
Depomed